Neoadjuvant Chemotherapy with Oxaliplatin plus Fluorouracil l-Leucovorin or Oxaliplatin plus Capecitabin and MoAb for resectable colorectal liver metastases(CML) from tokai digestive cancer trials group

ABSTRACT: Interventions: Patients receive FOLFOX regimen or XELOX (oxaliplatin plus capecitabin) and MoAb as neoadjuvant protocol Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

DISEASE(S): Resectable Liver Metastases From Colorectal Cancer

PROVIDER: 2619252 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR